PlacebosControversy exists regarding the ethics of using placebo control groups in clinical trials when effective treatments exist. The debate was fuelled by the announcement of the fifth revision of the Declaration of Helsinki in 2000. This study reviews the history and scientific background ...
Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol 2016;15:736-47.Benedetti F, Carlino E, Piedimonte A. , Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol 2016;15:736...
In medicine, patients often trust medical staff unconditionally and believe that their illness will be cured due to a medical phenomenon known as the placebo effect. In other words, patient-physician trust is vital in improving patient care and the effectiveness of their treatment [105]. For the...
Results from placebo-controlled trials of antidepressants have demonstrated that a large proportion of depressed patients show a significant improvement of symptoms while receiving placebo. In some patients, the improvement may be due to the natural course of the illness, independent of any therapeutic ...
clinicalcorrelations.org 相似文献The placebo response in medicine: minimize, maximize or personalize? Our understanding of the mechanisms mediating or moderating the placebo response to medicines has grown substantially over the past decade and offers the o... P Enck,U Bingel,M Schedlowski,... ...
Immune-mediated inflammatory diseases (IMIDs) are characterized by excessive and uncontrolled inflammation and thrombosis, both of which are responsible for organ damage, morbidity and death. Platelets have long been known for their role in primary haemostasis, but they are now also considered to be ...
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92:2977–83. Article CAS PubMed Google Scholar Mushannen T, Cortez P, Stanford FC, Singhal...
The PARTHENON program is a series of completed and ongoing phase III clinical trials investigating the efficacy and safety of ticagrelor in atherosclerotic CVD in comparison with established antiplatelet therapy or placebo. The overall aim of the program is to determine if more potent antiplatelet ...
Statistical analysis of combination drug trials, particularly the appropriateness of factorial analysis, is also discussed.doi:10.1016/0197-2456(89)90021-4Gordon PledgerElsevier Inc.Controlled Clinical TrialsPledger G. (1989). The role of a placebo-treated control group in combination drug trials. ...
Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein VI, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial. JAMA Cardiol. 6, ...